I would like to invite you to take part in our research study, which is investigating anxiety and depressive symptoms in the Spanish population during the COVID-19 outbreak.

We have an online questionnaire

That takes about 30 min to complete. We also ask that you please share this with all your networks, friends and family accross Spain. We greatly appreciate your assistance. Below is the invitation email which you could use to forward via email invitation.


Last Publications


libro personas mayores

A Practice Primer

English Version

May 2019


Vol.9 Sistema Dopaminérgico y Trastornos Psiquiátricos

Vol.10 Staging Neuropsychiatric Disorders: Implications for Etiopathogenesis and Treatment

June 2013

ISBN: 978-1-4614-7263-6

Next Course

November, 11th and 12th 2019

XIII Intensive Theoretical-Practical Course of update in Electroconvulsive Therapy

More information

Last Meeting

June, 20th-21th 2014

"Relevance of Staging Psychotic disorders as a Paradigm-shift for understanding disease progression and stage-dependent treatment"

More information


Vol.8 Implications of Comorbidity for Etiology and Treatment of Neuropsychiatric Disorders

Vol.8 Implications of Comorbidity for Etiology and Treatment of Neuropsychiatric Disorders

June 2007

Editors: Tomás Palomo, Richard J. Beninger, Trevor Archer, Richard M. Kostrzewa

Publisher: Editorial CYM, General Oráa, 47, 28006 MADRID

ISBN: 978-84-934250-0-5

Pages: 698

More information

Also found within the publication, are contributions presented at the meeting held in Mazagón in 2005.

Table of contents

PART 1. Comorbidity and Brain Disease: Neuronal Substrates

  1. Comorbidity Implications in Brain Disease: Neuronal Substrates of Symptom Profiles. Tomás Palomo, Richard J. Beninger, Richard M. Kostrzewa and Trevor Archer
  2. The Anatomy of co-Morbid Neuropsychiatric DisordersBased on Cortico-Limbic Synaptic Interactions. Susan Totterdell
  3. Disruption of Cortical-Limbic Interaction as a Substrate for Comorbidity. Anthony A. Grace
  4. Behavioural Sensitization in Addiction, Schizophrenia, Parkinson´s Disease and Dyskinesia. Werner J. Schmidt and Richard J. Beninger
  5. Cognitive Impairment and fMRI in Major Depression. Klaus Ebmeier, Emma Rose and Douglas Steele
  6. MAPK and CaMKII-mediated Events During MemoryFormation. Martín Cammarota, Lia R. Bevilaqua, Janine I. Rossato,Carolina Zinn, Jorge H. Medina and Iván Izquierdo
  7. The Connection Between the Hippocampal and the Striatal Memory Systems of the Brain: a Review of Recent Findings. Iván Izquierdo, Lia R.M. Bevilaqua, Janine I. Rossato, Juliana S. Bonini, Weber C. Da Silva, Jorge H. Medina and Martín Cammarota
  8. Subchronic Administration of Haloperidol Influences the Functional Deficits of Postnatal Iron Administration in Mice. Anders Fredriksson and Trevor Archer
  9. Obsessive-Compulsive Disorder as a Disturbance of Security Motivation: Constraints on Comorbidity. Henry Szechtman and Erik Z. Woody
  10. Schizophrenia as an Inflammation-Mediated Dysbalance of Glutamatergic Neurotransmission Norbert Müller and Markus Schwarz
  11. Inflammation and Depression: Is There a Causal Connection with Dementia? Brian E.Leonard and Ayemu Myint

PART 2. Comorbidity and Brain Disease: Symptom Profiles

  1. Comorbidity of Substance Abuse with Other Psychiatric Disorders. Tomás Palomo, Trevor Archer, Richard M. Kostrzewa and Richard J.Beninger
  2. Animal Models and Treatments for Addiction and Depression Co-morbidity. Neil E. Paterson and Athina Markou
  3. The Vulnerability to Alcohol and Substance Abuse in Individuals Diagnosed with Schizophrenia. John H. Krystal, D. Cyril D'souza, Jürgen Gallinat, Naomi Driesen, Anissa Abi-Dargham, Ismene Petrakis, Andreas Heinz and Godfrey Pearlson
  4. Neuroplasticity in Postsynaptic Density Proteins in an Animal Model of Addiction and Schizophrenia Comorbidity. Shigenobu Toda and Peter W. Kalivas
  5. Are Drugs of Abuse Reinforcing in Patients with Schizophrenia Because They Ameliorate a State of NMDA Deficiency? Bita Moghaddam
  6. Importance of Clinical Diagnoses for Comorbidity Studies in Substance Use Disorders. Marta Torrens, Rocío Martin-Santos and Sharon Samet
  7. Substance Use Disorders and Schizophrenia: a Question of Shared Glutamatergic Mechanisms. Joseph T. Coyle

PART 3. Comorbidity and Brain Disease: Genetic Variation

  1. Genetic Variation and Shared Biological Susceptibility Underlying Comorbidity in Neuropsychiatry. Tomas Palomo, Richard M. Kostrzewa, Rick J. Beninger And Trevor Archer
  2. From Dopaminergic Genes to Psychiatric Disorders. Janet Hoenicka, María Aragüés, Guillermo Ponce, Roberto Rodríguez-Jiménez, Miguel A. Jiménezarriero and Tomás Palomo
  3. Are Some Genetic Risk Factors Common to Schizophrenia, Bipolar Disorder and Depression? Evidence from DISC1, GRIK4 and NRG1. Douglas H.R. Blackwood, Ben J. Pickard, Pippaa. Thomson, Kathryn L. Evans, David J. Porteous and Walter J. Muir
  4. Association in Alcoholic Patients Between Psychopathic Traits and the Additive Effect of Allelic Forms of the CNR1 and FAAH Endocannabinoid Genes, and the 3´ Region of the DRD2 Gene. Janet Hoenicka, Guillermo Ponce, Miguel A. Jiménezarriero, Israel Ampuero, Roberto Rodríguez-Jiménez, Gabriel Rubio, Maria Aragüés, Jose A. Ramos and Tomás Palomo

PART 4. Comorbidity and Brain Disease: Treatment Strategies

  1. Treatment Consideration and Manifest Complexity in Comorbid Neuropsychiatric Disorders. Tomas Palomo, Richard M. Kostrzewa, Richard J. Beninger and Trevor Archer
  2. Common Efficacy of Psychotropic Drugs in Restoring Stressinduced Impairment of Prefrontal Plasticity. Nathalie Dupin, François Mailliet, Cyril Rocher, Karima Kessal, Michael Spedding and Therese M. Jay
  3. Dopaminergic Dysbalance in Distinct Basal Ganglia Neurocircuits: Implications for the Pathophysiology of Parkinson´s Disease, Schizophrenia and Attention Deficit Hyperactivity Disorder. C. Mehler-Wex, P. Riederer and M. Gerlach
  4. Implications of co-Morbidity for Etiology and Treatment of Neurodegenerative Diseases with Multifunctional Neuroprotective-Neurorescue Drugs; Ladostigil. Moussa B.H. Youdim, Tamar Amit, Orit Bar-Am, Orly Weinreb and Merav Yogev-Falach
  5. Depressive Comorbidity in Patients with Somatic Pathology A. Lobo, P. Saz, G. Marcos, A. Sarasola, M.F. Barcones, A. Bulbena, J. De Pablo, J.M. Farré, E. García-Camba, J. García-Campayo, M. Girón, M. Lozano, T. Palomo, L. Salvador, A. Campayo and Members Of The Repep Workgroup
  6. Dopamine and Incentive Learning: a Framework for Considering Antipsychotic Medication Effects. Richard J. Beninger
  7. Comorbidity of Schizophrenia and OCD: Clinical Aspects, Neurobiology and Treatment Abraham Weizman, Ronit Weizman, Camil Fuchs, Amos Frisch and Michael Poyurovsky
  8. The Family of Sensorimotor Gating Disorders: Comorbidities or Diagnostic Overlaps? Mark A. Geyer
  9. Modeling Tardive Dyskinesia: Predictive 5-HT2C Receptor Antagonist Treatment. Richard M. Kostrzewa, Nuo-Yu Huang, John P. Kostrzewa, Przemyslaw Nowak and Ryszard Brus
  10. Pharmacotherapy for Schizophrenia and co-Occurring Substance Use Disorders. Alan I. Green
  11. Psychological Intervention for Psychosis and Substance Misuse. Christine Barrowclough
  12. Atypical Effects of Atypicals in Schizophrenia. Vicente Molina
  13. Epilepsy and Affective Disorder: Clincal Manifestations and Pathophysiological Considerations. Thomas G. Bolwig

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817

Resolución mínima: 1024 x 768. Navegadores recomendados: Google Chrome / Firefox 3.5+ / Internet Explorer 9.0+ / Opera 9.0+ / Safari 3.0+